ALLO - Allogene Therapeutics, Inc.

ALLO

$2.39 +0.07 (+3.02%)

After Hours: $2.39 +0.00 (+0.00%)

Last updated: Apr 22, 2026 21:02

52-Week Range

$2.39

$0.86 $2.39 $4.46

Fundamentals Overview

Allogene Therapeutics, Inc. is in the middle of its 52-week range with moderate valuation, trending upward today.

Valuation moderate

P/B 1.8

Risk (Beta)

0.54 — lower vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 64% confidence Risk: Lower Volatility — Beta 0.54. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Sentiment improving (3 upgrades) · 3M vs S&P 500: +47.3% · 3M vs Healthcare sector: +58%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$582.63M

P/E (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

52-Week Range

$0.86 - $4.46

Volume vs Avg

N/A

Beta

0.54

About

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I cl...

Sector: Healthcare

Headquarters: US

Employees: 226

IPO Date: Oct 2018

Website: www.allogene.com

Beta: 0.54 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: C-. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 12, Market Outperform: 3, Market Perform: 3, Neutral: 2, Outperform: 6, Overweight: 3, Underweight: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $-0.12; current price is $2.39. That’s a -104.9% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric	Value
Valuation
P/E (TTM)	N/A
PEG (TTM)	N/A
P/B (TTM)	1.8
P/S (TTM)	N/A
Liquidity & enterprise
Current Ratio (TTM)	7.93
Quick Ratio (TTM)	7.93
Cash Ratio (TTM)	1.59
Profitability
ROE (TTM)	N/A
ROA (TTM)	N/A
Revenue growth (YoY)	N/A
Net margin (TTM)	0%
Gross margin (TTM)	0%
Operating margin (TTM)	0%
Debt to equity (TTM)	N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for ALLO.

Analyst Sentiment at a Glance

C- Sentiment Improving

Buy 12Market Outperform 3Market Perform 3Neutral 2Outperform 6Overweight 3Underweight 1

3 upgrades, 2 downgrades

Price Target Consensus

Current $2.39

Median $6.43

Consensus $6.43

Low consensus $3.85

High consensus $9.00

Stock Grades (Institutions)

Institution	Action	Previous Grade	New Grade	Date
HC Wainwright & Co.	maintain	Buy	Buy	2026-04-16
JP Morgan	upgrade	Underweight	Neutral	2026-04-16
Jefferies	maintain	Buy	Buy	2026-04-15
Baird	maintain	Outperform	Outperform	2026-04-14
Argus Research	maintain	Market Perform	Market Perform	2026-04-14
Citizens	maintain	Market Outperform	Market Outperform	2026-04-14
HC Wainwright & Co.	maintain	Buy	Buy	2026-04-14
Bernstein	maintain	Market Perform	Market Perform	2026-04-14
Piper Sandler	maintain	Overweight	Overweight	2026-03-13
Canaccord Genuity	maintain	Buy	Buy	2026-03-13
Citizens	upgrade	Market Perform	Market Outperform	2026-01-09
JP Morgan	downgrade	Neutral	Underweight	2025-10-10
JP Morgan	downgrade	Overweight	Neutral	2025-08-04
JMP Securities	maintain	Market Perform	Market Perform	2025-08-04
Oppenheimer	maintain	Outperform	Outperform	2025-08-01
Citigroup	maintain	Buy	Buy	2025-05-15
Truist Securities	maintain	Buy	Buy	2025-05-14
RBC Capital	maintain	Outperform	Outperform	2025-05-14
Baird	maintain	Outperform	Outperform	2025-05-14
Oppenheimer	maintain	Outperform	Outperform	2025-05-14
Piper Sandler	maintain	Overweight	Overweight	2025-05-14
HC Wainwright & Co.	maintain	Buy	Buy	2025-03-19
RBC Capital	maintain	Outperform	Outperform	2025-03-14
Citizens Capital Markets	upgrade	Market Perform	Market Outperform	2025-03-14
Canaccord Genuity	maintain	Buy	Buy	2025-03-14
Piper Sandler	maintain	Overweight	Overweight	2024-11-14
HC Wainwright & Co.	maintain	Buy	Buy	2024-11-08
HC Wainwright & Co.	maintain	Buy	Buy	2024-10-30
HC Wainwright & Co.	maintain	Buy	Buy	2024-08-15
Truist Securities	maintain	Buy	Buy	2024-08-09